Correction of the single cell RNA sequencing GENCODE gene model enables accurate detection and study of the novel target PVRIG, advancing research that could potentially deliver new cancer immunotherapies.
New researchers at Compugen, a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, is enabling accurate detection and study of the functional relevance of the novel target PVRIG following correction of the GENCODE gene model.
“One of the biggest challenges in bringing new treatments to cancer patients, is understanding the complex disease biology,” said Anat Cohen-Dayag, Ph.D., President, and CEO of Compugen. “Single cell technology has revolutionized the study of cell populations, particularly immune cells and has been a key technology used by many scientists involved in cancer immunotherapy research. The research… identified an inaccuracy in the single cell gene model technology. By correcting the GENCODE gene model, the most widely used gene model in single cell analysis platforms, we believe that we are enabling a more accurate detection of PVRIG, thereby facilitating the advancement of worldwide research of this pathway. We believe that this advancement could lead to the development of new cancer immunotherapies. As a leader in the DNAM-1 axis space, targeting both PVRIG and TIGIT pathways, we are focused on proof-of-concept studies in cancer patients treated with the triple combination of our potential first-in-class anti-PVRIG, COM701 our potential best-in-class anti-TIGIT, COM902, and a PD-1 inhibitor, with the goal of maximizing clinical benefit for patients.”
Compugen will present the new research at the American Association for Cancer Research (AACR) annual meeting on April 14-19, 2023, in Orlando, Florida.
Source – PRNewswire